Ticker Details
ADMA Biologics Inc ADMA Biologics Inc is a biopharmaceutical company. The company develops and manufactures specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases.
IPO Date:	October 18, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.04B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.18 | 3.02%
Avg Daily Range (30 D):	$0.16 | 1.85%
Avg Daily Range (90 D):	$0.31 | 2.99%

Institutional Daily Volume
Avg Daily Volume:	1.6M
Avg Daily Volume (30 D):	2.43M
Avg Daily Volume (90 D):	4.82M

Trade Size
Avg Trade Size (Sh.):	169
Avg Trade Size (Sh.) (30 D):	94
Avg Trade Size (Sh.) (90 D):	116

Institutional Trades
Total Institutional Trades:	2,430
Avg Institutional Trade:	$3.5M
Avg Institutional Trade (30 D):	$5.28M
Avg Institutional Trade (90 D):	$4.32M
Avg Institutional Trade Volume:	.31M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.95M
Avg Closing Trade (30 D):	$7.68M
Avg Closing Trade (90 D):	$8.98M
Avg Closing Volume:	535.93K

News

Jul 19, 2026 @ 12:42 PM ADMA BIOLOGICS DEADLINE: ROSEN, THE FIRST FILING F... Source: Rosen Law Firm

Jul 17, 2026 @ 4:53 PM Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareh... Source: Glancy Prongay Wolke & Rotter Llp

Jul 16, 2026 @ 4:00 PM Bronstein, Gewirtz & Grossman LLC Urges ADMA Biolo... Source: Bronstein, Gewirtz & Grossman Llc

Jul 13, 2026 @ 11:21 PM ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages A... Source: Rosen Law Firm

Jul 11, 2026 @ 5:37 AM רוזן, חברת שפ×Â... Source: Rosen Law Firm

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$.69	$.19	$.21
Diluted EPS	$.68	$.19	$.2
Revenue	$509.86M	$114.49M	$139.16M
Gross Profit	$312.42M	$80.75M	$88.82M
Net Income / Loss	$165.35M	$45.33M	$49.38M
Operating Income / Loss	$214.84M	$58.27M	$62.75M
Cost of Revenue	$197.45M	$33.74M	$50.35M
Net Cash Flow	$66.53M	$50.52M	$26.25M
PE Ratio